Follow-up studies are needed to validate the efficacy of RAM for gastric cancer through clinical, cellular, and animal experiments; our screened methylation biomarker NR3C1 should be analyzed further; the reliability of the target should be validated through gene silencing and other means; and the target should be analyzed through immunoprecipitation and other related techniques. Here, NR3C1 is linked to gastric cancer.